AWARENESS
The Canadian Cancer Theranostics Foundation (CCTF) is passionately committed to advancing awareness of cutting-edge Theranostics in cancer diagnostic imaging and therapeutic PRRT treatments. Our mission extends beyond simply highlighting the approved PRRT indications; we strive to champion and promote innovative and orphan PRRT applications in Alberta and beyond.
​
Our goal is to advance the understanding and application of theranostics in the treatment of neuroendocrine tumors and prostate cancer. We are dedicated to inform medical professionals and the public with the latest information and best practices to enhance patient outcomes and innovative care.
​
Together, we can revolutionize cancer care and empower patients with knowledge and access to transformative therapies.
Join us in our vital mission to make a difference in the lives of those affected by cancer.
RESEARCH
Our foundation is committed to support state-of-the-art technology for the diagnosis of neuroendocrine tumors.
We aim to support innovative solutions and facilitate the attraction and sponsorship of clinical trials that enhance patient outcomes.
Through these initiatives, we strive to create a significant impact in neuroendocrine tumor research and treatment, positioning Alberta as a leader in the battle against these tumors.
ADVOCACY
Introducing Alberta's inaugural initiative focused on advocationg for theranostics in cancer patients.
Currently, the only 2 approved indications of Theragnostic/PRRT in USA and Canada are for Neuroendocrine tumors and Prostate cancer.
Lutathera marked the first approved indication of PRRT for treatment t of SSTR-positive GEP-NETs (Gastro-Entero-Pancreatic NETs), based on results of NETTER-1 landmark trial, initially published in 2017. Pluvicto was the second approved indication of PRRT in mCRPS (metastatic castrate-resistant Prostate cancer) based on results of VISION Trial, published in 2019.
​
Alberta marked a historic milestone in Feb 2025, folowing Ministerial approval of fully funded applications of both Lutathera and Pluvicto as Standard of Care Treatments.
Our journey begins with neuroendocrine tumors and prostate cancer, but our vision extends far beyond. We are pushing boundaries across a diverse range of cancers—including lung, breast, and pancreatic—as well as exploring breakthroughs in metabolic, cardiovascular, and neurological conditions. With every step, we aim to bring renewed hope to patients and transform the future of care.
​
Together, we strive to build a communication bridge that empowers and supports those impacted by cancer.
EDUCATION
FUNDRAISING EVENTS
CCTF organizes various fundraising events to support cancer patients, raise awareness, and fund medical research. These events are a great opportunity to contribute to the cause and make a difference.
Welcome to our educational hub, dedicated to empowering patients, caregivers, and families throughout Alberta.
This platform offers a comprehensive array of resources, including robust online educational materials, printed guides and details about our Annual Scientific Meetings.
We are committed to enhancing community well-being through informed support and knowledge. Join us in advancing health literacy and understanding for neuroendocrine tumours and beyond.